Advisory Board
Adeoye Olukotun MD, MPH, FACC
Senior Physician Executive
Dr. Olukotun has over 30 years of experience in the pharmaceutical industry. He is currently the CEO of CR Strategies, LLC, a clinical research and development consulting firm. Prior to this, he was the CEO of Epigen Pharma, vice chairman of Cardiovax Inc., a biotech company developing innovative cardiovascular therapies, co-founder and CMO of VIA Pharmaceuticals, and CMO of Mallinckrodt, Inc. He has held executive roles at BMS and other companies.
Iftikhar Kullo MD
Clinician
Dr. Iftikhar J. Kullo is at Mayo Clinic, Rochester MN. His research interests include biomarkers of cardiovascular risk. Through his Atherosclerosis and Lipid Genomics Laboratory, Dr. Kullo is investigating the use of new methodologies in refining cardiovascular risk stratification. These include genetic markers, circulating biomarkers, and noninvasive tests of arterial function and structure.
Martin Bogsrud MD, PhD
Clinician
Dr. Bogsrud is a member of the Atherosclerosis and Lipidology group at the Department of Endocrinology, Morbid Obesity, and Preventive Medicine at Oslo University Hospital. Martin has significant research and clinical experience in familial hypercholesterolemia, a genetic lipid disorder that predisposes individuals to a high risk of atherosclerotic cardiovascular disease (ASCVD).
Michael Boffa PhD
Biochemistry and Pharmacology
Dr. Boffa received his doctorate from Queen’s University, Canada, and is currently an associate professor at the Robarts Research Institute, Ontario. His research group is pursuing studies of structure/function relationships in TAFI, using molecular biological and protein biochemical approaches. They have made key contributions to the understanding of the mechanisms of regulation of the gene encoding TAFI and continue to pursue new avenues of research in this area.
Marlys Koschinsky PhD
Biochemistry and Pharmacology
Dr. Koschinsky received her doctorate in Molecular Genetics of Human Ceruloplasmin from the University of British Columbia and is presently a professor at the Department of Physiology & Pharmacology, Schulich School of Medicine & Dentistry. Dr. Koschinsky’s research focuses primarily on lipoprotein(a) (Lp(a)), a causal risk factor for coronary heart disease.
Somanath Shenoy, PhD, FAHA
Pharmacology and Experimental Therapeutics
Dr. Shenoy is a professor at the University of Georgia, Augusta. His research laboratory is pursuing the development of new and innovative therapeutics for acute lung injury (ALI), acute respiratory disease syndrome (ARDS), angiogenesis and fibrosis-dependent clinical conditions, and cancers of the prostate, bladder, and colon. His primary focus of our research is on protein kinase B (Akt), a serine-threonine kinase, and associated signaling partners on mediating these processes.
Andrea Sikora Newsome BCPS, BCCCP
Critical Care Pharmacist
Andrea Sikora Newsome is a critical care pharmacist and clinical assistant professor at the College of Pharmacy, University of Georgia. Dr. Newsome’s research interests include the vascular and hemodynamic alterations in critical illness and critical care pharmacy practice.